Сахарный диабет (Mar 2022)

Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists

  • I. I. Dedov,
  • N. G. Mokrysheva,
  • M. V. Shestakova,
  • T. V. Nikonova,
  • A. Yu. Mayorov,
  • G. R. Galstyan,
  • M. Sh. Shamhalova,
  • V. O. Barysheva,
  • A. S. Ametov,
  • M. B. Antsiferov,
  • A. Yu. Babenko,
  • T. P. Bardymova,
  • F. V. Valeeva,
  • A. A. Vachugova,
  • E. N. Grineva,
  • T. Yu. Demidova,
  • T. P. Kiseleva,
  • M. A. Kunicyna,
  • T. N. Markova,
  • A. M. Mkrtumyan,
  • N. A. Petunina,
  • L. A. Ruyatkina,
  • V. V. Saluhov,
  • L. A. Suplotova,
  • E. L. Hadarceva,
  • Yu. Sh. Halimov

DOI
https://doi.org/10.14341/DM12873
Journal volume & issue
Vol. 25, no. 1
pp. 27 – 49

Abstract

Read online

A dangerous viral disease COVID-19, caused by a new RNA coronavirus SARS-COV-2, has been actively spreading in the world since December 2019. The main manifestations of this disease are bilateral pneumonia, often accompanied by the development of acute respiratory syndrome and respiratory failure. Patients with diabetes mellitus (DM) are at high risk of infection with the SARS-COV-2 virus, severe illness and death.Maintaining of target glycemic levels is the most important factor in a favorable outcome of COVID-19 in both type 1 and type 2 DM. The choice of antihyperglycemic therapy in a patient with DM in the acute period of COVID-19 depends on the initial therapy, the severity of hyperglycemia, the severity of the viral infection and the patient’s clinical condition.The article presents the recommendations of the board of experts of the Russian Association of Endocrinologists on glycemic control and the choice of antihyperglycemic therapy in patients with type 2 DM and COVID-19, and also on the use of glucocorticosteroids used in the treatment of COVID-19 in patients with type 2 DM.

Keywords